Jon Eckard, PhD, TYME Inc., explains Ongoing Phase II Pancreatic Cancer Trial Metabolic therapy is tumor-treating, patient-sparing at Annual Meeting 2018.
Ongoing Phase II Pancreatic Cancer Trial Metabolic therapy is tumor-treating, patient-sparing
Jon Eckard, PhD, TYME Inc., explains Ongoing Phase II Pancreatic Cancer Trial Metabolic therapy is tumor-treating, patient-sparing at Annual Meeting 2018.